Wockhardt’s Zaynich antibiotic surged stock by 75%. CEO Habil Khorakiwala cited its uniqueness; phase three trials end this fiscal year. Compared to Novo Nordisk’s Ozempic, Zaynich’s $25 billion potential counters global antibiotic resistance.
Post tariff tantrum, where could we see some positive surprises in Q1? Pashupati Advani explains
Pashupati Advani of Global Foray anticipates positive surprises in companies with lower tariffs and those leveraging arbitrage opportunities. He discusses the implications of tariff uncertainty